TIDMACPH 
 
 
   Acacia Pharma Becomes New Industry Supporter of the American Society of 
Anesthesiologists 
 
   Cambridge, UK and Indianapolis, US -- 21 April 2021, 07:00 CEST: Acacia 
Pharma Group plc ("Acacia Pharma", the "Group" or the "Company") 
(EURONEXT: ACPH), a hospital pharmaceutical company focused on the 
development and commercialization of new products aimed at improving the 
care of patients undergoing significant treatments such as surgery, 
other invasive procedures or cancer chemotherapy, is proud to be named a 
new Industry Supporter of the American Society of Anesthesiologists 
("ASA" or the "Society"). 
 
   Launched in 2010, ASA's Industry Supporter Program is limited to ten 
organizations. Participation is intended for companies who want to stand 
apart by showcasing high-level commitment to the education of physician 
anesthesiologists, the anesthesia care team and advancement of the 
specialty. 
 
   As an Industry Supporter, Acacia Pharma will help to establish a strong, 
mutually beneficial relationship with the anesthesiology community, 
strengthen collaboration between physician anesthesiologists and 
industry, and add to the value the Society provides to patients and the 
public, while providing invaluable year-round support of ASA programs 
and priorities related to improving perioperative care. 
 
   Through the program, Acacia Pharma will have unique opportunities to 
inform strategic dialogue with leaders in anesthesiology from around the 
world and during major ASA events including the ANESTHESIOLOGY(R) annual 
meeting and Practice Management(TM) conference. 
 
   Acacia Pharma has two FDA-approved anesthesiology products currently 
being launched in the U.S. The first is a new dopaminergic antiemetic 
approved for treatment and prophylaxis of postoperative nausea and 
vomiting (PONV), targeted at addressing the major unmet need in the 
rescue treatment of patients suffering with PONV. The second is a novel, 
rapid on/rapid off and reversible benzodiazepine approved for procedural 
sedation in adults undergoing procedures lasting up to 30 minutes, such 
as colonoscopy and bronchoscopy. 
 
   "We are excited to welcome Acacia Pharma as a new ASA Industry Supporter, 
" said ASA President Beverly K. Philip, M.D., FACA, FASA. "By working 
with our Industry Supporters, we aim to improve perioperative care. 
Acacia Pharma and our members working together will strengthen the 
Society's priorities of advancing the specialty through patient safety 
and practice initiatives." 
 
   "We are delighted to become an ASA Industry Supporter, the world's 
pre-eminent organization representing anesthesiologists," commented 
Acacia Pharma Chief Medical Officer Gabriel Fox, M.D. "This gives us a 
greatly valued opportunity to work with anesthesiologists across the 
country to improve the safety, outcomes and well-being of their 
patients. We look forward to a successful partnership for years to come 
and thank ASA for this opportunity." 
 
   Contacts 
 
 
 
 
Acacia Pharma Group plc             International Media 
 Mike Bolinder, CEO                  Mark Swallow, Frazer Hall, David 
 Gary Gemignani, CFO                 Dible 
 +44 1223 919760 / +1 317 505 1280   Citigate Dewe Rogerson 
 IR@acaciapharma.com                 +44 20 7638 9571 
                                     acaciapharma@citigatedewerogerson.com 
US Investors                        Media in Belgium and the Netherlands 
 LifeSci Advisors                    Chris Van Raemdonck 
 Irina Koffler                       +32 499 58 55 31 
 +1 917-734-7387                     chrisvanraemdonck@telenet.be 
 ikoffler@lifesciadvisors.com 
 
 
   About Acacia Pharma 
 
   Acacia Pharma is a hospital pharmaceutical company focused on the 
development and commercialization of new products aimed at improving the 
care of patients undergoing significant treatments such as surgery, 
other invasive procedures, or cancer chemotherapy. The Company has 
identified important and commercially attractive unmet needs in these 
areas that its product portfolio aims to address. 
 
   Acacia Pharma's first product, BARHEMSYS(R) (amisulpride injection) is 
available in the US for the management of postoperative nausea & 
vomiting (PONV). 
 
   BYFAVO(TM) (remimazolam) for injection, a very rapid onset/offset IV 
benzodiazepine sedative is approved and launched in the US for use 
during invasive medical procedures in adults lasting 30 minutes or less, 
such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion 
UK Limited for the US market. 
 
   APD403 (intravenous and oral amisulpride), a selective dopamine 
antagonist for chemotherapy induced nausea & vomiting (CINV) has 
successfully completed one proof-of-concept and one Phase 2 dose-ranging 
study in patients receiving highly emetogenic chemotherapy. 
 
   Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D 
operations are centred in Cambridge, UK. The Company is listed on the 
Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker 
symbol ACPH. 
 
   Acacia Pharma Group plc 
 
   The Officers' Mess, Royston Road, Duxford, Cambridge, CB22 4QH, United 
Kingdom 
 
   Company number 9759376 
 
   www.acaciapharma.com 
 
   About The American Society Of Anesthesiologists 
 
   Founded in 1905, the American Society of Anesthesiologists (ASA) is an 
educational, research and scientific society with more than 54,000 
members organized to raise and maintain the standards of the medical 
practice of anesthesiology. ASA is committed to ensuring physician 
anesthesiologists evaluate and supervise the medical care of patients 
before, during and after surgery to provide the highest quality and 
safest care every patient deserves. 
 
   For more information on the field of anesthesiology, visit the American 
Society of Anesthesiologists online at asahq.org 
https://www.globenewswire.com/Tracker?data=XZk39bwcaFucGP-0FT0l3muBl4O0QH1G_zAp3ZifMKguKzAZmnB9KI10whHGQINOOzDH8pDueJjVcKGUGy2VcQ== 
. To learn more about the role physician anesthesiologists play in 
ensuring patient safety, visit asahq.org/ 
https://www.globenewswire.com/Tracker?data=XZk39bwcaFucGP-0FT0l3meZN6jk_9gSu2t7oFwOEucshbRcGh21h3NHJRvqdnHpgbmKnEwnoIVwgeHwuZpaWVYrGeCk0kpxVTnNhe-gYIM= 
MadeforThisMoment 
https://www.globenewswire.com/Tracker?data=40PSLDc8Ac2UOEjOJ9mxGmL_W9hu-R8nyAIFs2W2kz_PaPQ0zGFN80OPNIGwsTRObnL5JeSGoltF8Bvzamc5hD5PHd0HlaSF0PCTfchvKxIZrPKfqIec78vu8DLjAcaI 
. Like ASA on Facebook 
https://www.globenewswire.com/Tracker?data=CgwHa2Uiv2oySf-EX9c4n99kLF9IMEpNUbneTkzxC4zLG0m3t5uTwmdM0sHqskNy5PjfDnAFeCl0CBEPqDsTSnyqcxIiJCcIgzHJxVrhf4YQ0agJ3WVVB5m8asvynB8V 
, follow ASALifeline 
https://www.globenewswire.com/Tracker?data=PGTD9fBNiTjFDtFYtWD3X1dKWdjRJ1EDE61wxIATeucxkIcXxyHDbZIGeebkIT5rC1wHx1mz_-Ye0LdRdp-BXRYetF7Mo--ROtqX0irKd4k= 
on Twitter. ASA hosts the ANESTHESIOLOGY(R) annual meeting 
https://www.globenewswire.com/Tracker?data=K81xlx8jsGgqfHt12_WcefA0AppXWcSR1g3endaAAWMUHjPi0b8Os0NlAwPXbAVFLQ6lwS4AVwcEJhLex92Vmpg79Lwwy4YACqLVYVn12oikqLzUeAFPiHMceYEYxFdRN8mdyWfl9cGy3iMhGN2Krw== 
, the largest, most comprehensive conference in the specialty with 
world-class education, the latest research and innovations, and the 
chance to recharge with colleagues, Oct. 8-12, 2021 in San Diego. Unable 
to attend in person, sign up for the Virtual Track which will offer a 
curated selection of presentations. 
 
   Attachment 
 
 
   -- NL - ACPH Press release ASA 210421 
      https://ml-eu.globenewswire.com/Resource/Download/4405770e-f3c1-4928-af1b-e5d8df1af6ff

(END) Dow Jones Newswires

April 21, 2021 01:00 ET (05:00 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Acacia Pharma Charts.
Acacia Pharma (LSE:0PNT)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Acacia Pharma Charts.